Arcutis Biotherapeutics, Inc. ARQT Payment-in-kind interest
Payment-in-kind interest at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaidInKindInterest.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s payment-in-kind interest.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s payment-in-kind interest?
- Arcutis Biotherapeutics, Inc. (ARQT) reported payment-in-kind interest of $461K in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s payment-in-kind interest changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s payment-in-kind interest increased by 11.1% year-over-year, from $415K to $461K.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s payment-in-kind interest?
- Over 3 years (2022 to 2025), Arcutis Biotherapeutics, Inc.'s payment-in-kind interest has grown at a -12.3% compound annual growth rate (CAGR), from $2.61M to $1.76M.
- What does payment-in-kind interest mean?
- Represents interest expense that is settled through the issuance of additional debt or equity instruments rather than cash payments. This metric is critical for assessing a company's cash conservation strategy and potential future dilution or debt burden. It highlights non-cash financing costs that impact the long-term capital structure.